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ABSTRACT
Introduction: Systemic corticosteroids are anti-inflammatory agents with dexamethasone among
the most potent in the class. Within (respiratory) allergy, systemic corticosteroids are usually
applied in medical emergencies. In these situations, patients may experience physical or logistic
problems taking tablets. To fulfil a practical unmet need for outpatients, Dexa ODF, an oral
dissolvable film containing dexamethasone, was developed.
Objectives: We compared the safety, tolerability and pharmacokinetics (PK) of Dexa ODF with
Fortecortin tablets in healthy subjects.
Methods: Thirty subjects participated in this open label, two-way, cross-over study, consisting of
two treatment visits separated by 5–10 days. On both treatment visits, subjects randomly
received one single dose of Dexa ODF (one strip; 8 mg dexamethasone) or one single dose of
Fortecortin (two 4 mg tablets). Safety evaluations and blood sampling for PK were conducted
until 48 h post-dose and bioequivalence analysis was performed on AUC(0-t), AUC(0-∞) and
Cmax.
Results: All subjects were dosed. Forty-five adverse events (AEs) were reported by 17 subjects
and approximately 50% were deemed ‘possibly treatment related’ (14 on Dexa ODF; 12 on
Fortecortin) with no significant difference between treatments. For all three bioequivalence
parameters the 90% CIs were within the acceptance limits of bioequivalence (0.8;1.25).
Conclusion: We demonstrated good tolerability and bioequivalence of Dexa ODF (8 mg dex-
amethasone) compared to Fortecortin tablets (2 × 4 mg dexamethasone). Dexa ODF is currently
under development as an innovative treatment for use within respiratory and allergic conditions,
including emergencies.
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Systemic corticosteroids are potent anti-inflammatory
agents that are being used in several therapeutic areas for
over 70 years.Within this class, several drugs with different
potencies and durations of action have been developed.
Among these, hydrocortisone is short-acting and the least
potent, prednisone, prednisolone and methylprednisolone
are intermediate-acting and intermediate-potent, while
dexamethasone provides long-lasting effectiveness with a
potency approximately four to five times higher than ‘the
intermediate group’.[1,2]
Therapeutic indications for systemic corticosteroids
vary from acute (rescue) use, as in allergic and respira-
tory emergencies, to maintenance or adjuvant therapy
as, for instance, in chronic inflammatory and parench-
ymal lung diseases, Addison’s disease, brain edema,
autoimmune diseases, transplantation medicine and as
treatment for chemotherapy-induced nausea and
vomiting (CINV).[3–8]
According to guidelines, oral corticosteroids are
advocated to treat severe asthma exacerbations, espe-
cially in general practice.[9] During exacerbations or
other allergic emergencies, patients may experience
problems with taking currently available oral medica-
tions, for example because no water is available or
because of severe distress. In non-acute situations,
and particularly for CINV patients, swallowing tablets
may also impose a problem because the patient is
nauseous or in a terminal stage.
As a solution to these medical conditions, and to
fulfill a practical unmet need, a patient-friendly formu-
lation consisting of an oral dissolvable film (ODF)
containing dexamethasone has been developed. The
CONTACT Zuzana Diamant z.diamant@gems.demon.nl
EUROPEAN CLINICAL RESPIRATORY JOURNAL, 2017
VOL. 4, 1353395
https://doi.org/10.1080/20018525.2017.1353395
© 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided the original work is properly cited.
choice of the corticosteroid for this product was based
on its potency, allowing applications both in acute
allergic conditions (including anaphylaxis) and respira-
tory emergencies as well as in more chronic conditions
such as CINV, brain metastasis and edema. These
applications typically require single doses of dexa-
methasone of 4–8 mg or higher and hence, 8 mg was
chosen for this product but it can also be produced in
other strengths, e.g. 4 mg.
Here, we report a phase I study comparing the
pharmacokinetic profiles, safety and tolerability of a
single dose of Dexa ODF (one strip of 8 mg dexa-
methasone) with a single dose of the registered dexa-
methasone tablet Fortecortin (two tablets of 4 mg
dexamethasone each) in healthy subjects.
Subjects and methods
Subjects
Thirty healthy male subjects participated in this study.
All subjects declared being in good general health with-
out any history of clinically relevant disorders, with no
clinically relevant abnormalities on physical examina-
tion, vital signs, routine laboratory and ECG at screen-
ing. Main exclusion criteria consisted of any relevant
prior medical condition, prior history of abuse of
drugs, tobacco or alcohol, relevant (drug) allergies,
use of any concomitant medications (including herbals,
vitamins or minerals) and recent intake of cytochrome
P450 3A4-interacting agents (e.g. grapefruit or orange
containing foods).
This single center study was conducted at the
Clinical Trial Unit of Skane University Hospital in
Lund, Sweden, and had been approved by the
Regional Ethical Review Board as well as by the
Swedish Medical Products Agency. All subjects pro-
vided written informed consent before enrolment into
the study. All study-related procedures were conducted
in accordance with the Declaration of Helsinki and the
International Conference of Harmonization (ICH)
Guideline for Good Clinical Practice. The study was
registered under EUDRACT number 2013–001730-18.
Study design
This study had a randomized, open label, two-way,
cross-over design and consisted of a screening visit
(visit 1) to test subjects’ eligibility, followed by two treat-
ment visits (visit 2 and visit 3, respectively) separated by
a washout period of 5–10 days. There was a follow-up
visit (visit 4) after study finalization (Figure 1). On both
treatment visits, subjects randomly received a single dose
of the study medication (i.e. Dexa ODF or Fortecortin)
under fasting conditions. Blood samples were drawn at
predefined time points from pre-dose until 48 h post-
dose; in parallel, adverse events were recorded and safety
assessments were performed.
Study medication and dose selection
Test product
The test product, Dexa ODF (batch 7,018,863), is being
developed by AcuCort AB, Helsingborg, Sweden. Dexa
ODF is a thin oral dissolvable film, sized
20 × 33 × 0.025 mm, containing 8 mg dexamethasone.
Apart from micronized dexamethasone, Dexa ODF
contains the inactive ingredient hydroxypropyl methyl-
cellulose (HPMC). When placed on the tongue, Dexa
ODF rapidly dissolves in saliva and the active ingredi-
ent becomes available for systemic absorption.
Reference product
Fortecortin is a dexamethasone tablet that has been
approved for marketing in the EU. It is available in
strengths of 1, 4 and 8 mg (Merck, S.L., Madrid, Spain).
In this study, two Fortecortin tablets (batch M1337) of
4 mg each were administered as the reference product
and swallowed with a standardized volume of 150 ml
water.
Figure 1. Study design.
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In the test product (Dexa ODF, batch 7018863), the
content of dexamethasone was determined at 8.152 mg
per strip. For the reference product (Fortecortin, batch
M1337), the content of dexamethasone was determined
at 4.035 mg per tablet. Thus, two tablets of Fortecortin
administered to participants in this study yielded a
total dose of dexamethasone of 8.070 mg with an over-
all difference in dexamethasone content between test
and reference products of <1%.
According to Fortecortin’s SmPC (Summary of
Product Characteristics), the recommended initial
doses for adults with acute severe asthma are
8–20 mg and up to 48 mg.
Methods
During the treatment visits (visit 2 and 3), subjects were
fasted overnight for at least 8 h pre-dose until at least 4 h
post-dose. Standardized meals were provided at pre-set
timepoints, 4 and 10 h post-dose. During each treatment
visit, blood samples for PK analysis were drawn from a
cannula placed in the fore-arm at pre-dose (i.e. within
1 h pre-dose) and at 15, 30, 45, 60, 75, 90 and 105 min
and at 2, 2.5, 3, 5, 8 and 12 h (before discharge from the
unit) post-dose, and subsequently, at single ‘come back’
occasions at 24, 36 and 48 h (±1 h) post-dose. In parallel,
safety assessments were performed repeatedly by adverse
events recordings, physical examination, vital signs mea-
surements, safety laboratory tests and ECGs. Adverse
events were reported using MedDRA terminology.
Blood samples processing
Blood samples were centrifuged at approximately 3500
rpm for 10 min at 2–8°C. The plasma was carefully
removed using a pipette and stored in aliquots at −20°
C, within 4 h transferred to −80°C, pending analysis.
The concentration of dexamethasone in the plasma
samples was determined using a validated ultra-perfor-
mance liquid chromatographic-tandem mass spectro-
metric (UPLC-MS/MS) method. The bioanalytical
method validation included selectivity, linearity, preci-
sion, accuracy, dilution integrity, matrix effects and
stability issues. The development, validation and execu-
tion of this bioanalytical method were conducted at a
GLP certified contract laboratory (the National
Veterinary Institute, SVA, Uppsala, Sweden).
Statistical analysis
All 30 subjects were included in the statistical evalua-
tion. No adjustment for multiple testing was done. The
sample size of 30 subjects was based on previous
findings from current literature.[9] Based on intra-sub-
ject coefficients in this study, a sample size of 8 and 22
subjects was required to show bioequivalence at 90%
power and acceptance limits of 80–125% for AUC and
Cmax, respectively. Safety and tolerability were
reported using MedDRA terminology and summarized
by treatment group using descriptive statistics.
Pharmacokinetic analysis was performed by
Scandinavian Development Services AB, Danderyd,
Sweden. Pharmacokinetic parameters (tmax, Cmax,
T1/2, AUC(0-t) and AUC(0-∞)) for dexamethasone
were calculated from plasma samples obtained from
subjects during both dosing periods using standard
non-compartmental methods. Descriptive statistical
analysis for pharmacokinetic variables was based on
(i) subject listings, (ii) graphs and (iii) summary statis-
tics comprising geometric mean, coefficient of varia-
tion, arithmetic mean, standard deviation, median,
minimum and maximum, as appropriate. The coeffi-
cient of variation (CV,%) was calculated as:
100
Y
ðexp s2  1  (1)
with ‘s’ as the standard deviation of the data on a log
scale. The computational software used for the statis-
tical analysis was SAS®, version 9.3 (SAS institute inc.
NC, USA).
Differences in PK parameters of both dexamethasone
formulations (i.e. log-transformed ratios of AUC(0-t),
AUC(0-∞) and Cmax, and tmax) were tested using an
analysis of variance (ANOVA) or a non-parametric test,
as appropriate. The ANOVA model included ‘sequence’,
‘subject within sequence’, ‘period’ and ‘formulation’ as
fixed effects. An F-test was used to investigate whether
or not Cmax for Dexa ODF was lower than for
Fortecortin, using log-transformed ratios of Cmax. The
test was two-sided at significance level 5% (alpha = 0.05).
Wilcoxon paired signed rank test was used to compare
tmax for Dexa ODF versus Fortecortin. The test was
one-sided at significance level 5% (alpha = 0.05).
Additionally, AUC (0-t), AUC (0-∞) and Cmax
were tested for bioequivalence between formulations.
If the 90% confidence intervals for the log-transformed
ratios of AUC(0-t) were within acceptance limits
80–125%,[10] based on the back-transformed lower
and upper limits, this was interpreted as bioequivalence
between the two products.
Results
Safety and tolerability
Thirty-five healthy subjects were screened and 30 of
them were randomized. All randomized subjects
EUROPEAN CLINICAL RESPIRATORY JOURNAL 3
completed the study and were dosed both Dexa ODF
and Fortecortin (Table 1). In all, 17 subjects reported
45 AEs (26 AEs within Dexa ODF administration,
including two at follow-up; 19 AEs within
Fortecortin administration). Most frequent AEs con-
sisted of headache, fatigue and polyuria.
Approximately 50% of AEs were deemed ‘possibly
treatment related’ (14 on Dexa ODF and 12 on
Fortecortin) with no significant difference between
treatments. Forty-four AEs were self-limiting and
mild in intensity, while one AE was reported mod-
erate (neck pain, treatment unrelated). There were
no clinically relevant changes or trends observed in
vital signs, laboratory variables or ECGs in any of the
subjects during the study.
Pharmacokinetics and bioequivalence testing
Figure 2 shows the mean plasma concentrations over
time for both the test and reference product and
Table 2 shows a summary of the PK parameters for
both study formulations. No statistical difference was
found between Dexa ODF and Fortecortin in any PK
parameter, but Dexa ODF appeared to have a faster
absorption rate compared to Fortecortin (mean tmax
87 vs. 107.6 min, respectively), but failed to reach
statistical significance (p = 0.0575). In addition, PK
parameters AUC(0-t), AUC(0-∞) and Cmax met the
acceptance limits of bioequivalence (i.e. all 90% CIs
within 80–125%) (Table 3).
λz = terminal rate constant
Discussion
In this study, we evaluated and compared the safety, toler-
ability and pharmacokinetics (PK) of Dexa ODF, an inno-
vative dexamethasone formulation, with Fortecortin, a
dexamethasone tablet approved for marketing in the EU,
in 30 healthy males. Both products were generally well-
tolerated, and no safety issues occurred during the study.
Although slightly more AEs were reported after Dexa ODF
administration, these were all mild and self-limiting with
only a minority deemed to be ‘possibly treatment related’,
with no significant difference between the two products.
Both products showed a similar PK profile and bioequiva-
lence was met according to conventional criteria for AUC
and Cmax.
Our data complement the findings from a previous
study by Nishigaki et al. comparing the clinical efficacy of
another dexamethasone oral dissolvable film with a
Table 1. Demographics of randomized subjects.
























Figure 2. Mean (± SD) dexamethasone plasma concentration over time during both treatments.
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marketed dexamethasone tablet in nauseous patients with
breast cancer following chemotherapy.[11] In that study,
both dexamethasone products were administered at 8 mg
daily dose 2–4 days after combination chemotherapy.
Although both products offered a similar anti-emetic effi-
cacy, the patients preferred the oral dissolvable film over
the tablets due to its user friendliness and better taste.[11]
To further improve patient-friendliness for both chil-
dren and adults across different clinical indications, Dexa
ODF has also been developed in a 4 mg strength corre-
sponding to approximately 25 mg of prednisolone. The
Dexa ODF strength of 8 mg used in the current study
thus corresponds to approximately 50 mg of prednisolone.
Additionally, we compared the AUC(0-t) and Cmax
from our study with previously published PK data.
Following a PubMed search, we found eight human studies
reporting AUC(0-t) and Cmax for orally administered
dexamethasone doses between 0.5 mg and 300 mg.[12–
19] Although two of these studies [12,18] reported deviat-
ing results for various reasons, overall, it was concluded
that the pharmacokinetics of oral dexamethasone show
linearity and that the AUC and Cmax obtained for
Fortecortin (and Dexa ODF) in the current study fit in
with current literature.
Conclusion
In summary, we report a good safety and pharmacoki-
netics of an innovative dexamethasone oral product
currently under development for both children and
adults across several clinical indications including ana-
phylaxis, allergic syndromes, acute (asthmatic, COPD or
croup-related) airway obstruction and as supportive
therapy in debilitating conditions, such as cancer. Due
to its favorable pharmacokinetic profile, it can be a more
patient-friendly alternative to conventional oral tablets
of dexamethasone, prednisolone and other glucocorti-
coids in particular for outpatients with allergic or
respiratory emergencies or in nauseous patients.
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Table 2. Pharmacokinetic parameters following single doses of Dexa ODF and Fortecortin in healthy subjects.
Treatment
Parameter





Dexa ODF 8 mg AUC0-t (min*ng ml
–1) 30 24,490.0 8236.2 23,257.0 11,983.9 42,786.2 23,235.5 33.8
AUC0-∞ (min*ng ml
–1) 30 24,764.7 8263.8 23,650.4 12,154.0 43,266.8 23,514.2 33.5
Cmax (ng ml
–1) 30 72.7 19.1 69.1 38.7 118.2 70.3 26.8
tmax (min) 30 87.0 41.7 75.0 30.0 180.0 78.0 51.0
t½ (min) 30 251.9 52.6 236.9 141.7 416.1 246.9 20.6
λz 30 0.00286 0.00059 0.00293 0.00167 0.00489 0.00281 20.6
Fortecortin 2 × 4 mg AUC0-t (min*ng ml
–1) 30 26,032.5 9294.8 23,702.1 11,461.2 53,570.5 24,591.1 35.1
AUC0-∞ (min*ng ml
–1) 30 26,345.0 9322.1 24,174.1 11,597.4 54,024.4 24,906.4 34.9
Cmax (ng ml
–1) 30 73.0 18.3 75.0 33.8 110.3 70.5 28.7
tmax (min) 30 107.6 55.1 98.0 30.0 300.0 95.2 55.0
t½ (min) 30 253.9 44.7 252.9 190.4 400.8 250.5 16.4
λz 30 0.00280 0.00043 0.00274 0.00173 0.00364 0.00277 16.4
Table 3. Comparison of PK parameters of Dexa ODF 8 mg versus Fortecortin 2 × 4 mg in healthy subjects.
Treatment comparison
Dexa ODF 8 mg versus Fortecortin 2 × 4 mg
Parameter
(unit) n Geometric mean (ratio) 90% Confidence Interval p-value
AUC0-t (min*ng ml
–1) 30 0.945 (0.897, 0.995)
AUC0-∞ (min*ng ml
–1) 30 0.944 (0.898, 0.993)
Cmax (ng ml
–1) 30 0.998 (0.914, 1.089) two-sided: 0.964
tmax (min) 30 Dexa<Forte one-sided: 0.0575
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